Literature DB >> 11357402

[Efficient synthesis of natural alpha-conotoxins and their analogs].

M N Zhmak1, I E Kasheverov, Iu N Utkin, V I Tsetlin, O M Vol'pina, V T Ivanov.   

Abstract

An efficient scheme for the synthesis of alpha-conotoxins, containing 12-18 amino acid residues and two disulfide bridges, was proposed. Its advantages are: (1) the avoidance of orthogonal protections of Cys residues; (2) a lower number of stages in a cycle of the peptide chain elongation by the method of solid phase synthesis; (3) the linear product is sufficiently pure for being used at the next stage of the disulfide bond formation without additional purification; and (4) a substantially reduced time of oxidation to disulfides at pH 10, which led to the target product in a high yield. A number of natural alpha-conotoxins (GI, ImI, EI, MII, and SIA), affecting the muscle and neuronal nicotinic acetylcholine receptors of various types, and several new analogues of these conotoxins (in particular, [Tyr10]ImI, [Gln12]GI, and [Ser1]GI) were synthesized by this scheme. They were used for elucidating the spatial structure of alpha-conotoxins by 1H NMR spectroscopy and for studying the ligand-binding sites of their receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357402     DOI: 10.1023/a:1011319101676

Source DB:  PubMed          Journal:  Bioorg Khim        ISSN: 0132-3423


  2 in total

1.  A comparative study on selectivity of alpha-conotoxins GI and ImI using their synthetic analogues and derivatives.

Authors:  Igor E Kasheverov; Maxim N Zhmak; Innokenty V Maslennikov; Yuri N Utkin; Victor I Tsetlin
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

2.  α-conotoxins revealed different roles of nicotinic cholinergic receptor subtypes in oncogenesis of Ehrlich tumor and in the associated inflammation.

Authors:  T I Terpinskaya; A V Osipov; T E Kuznetsova; E L Ryzhkovskaya; V S Ulaschik; I A Ivanov; V I Tsetlin; Yu N Utkin
Journal:  Dokl Biochem Biophys       Date:  2015-09-03       Impact factor: 0.788

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.